Workshops for Children With Global Developmental Delays

June 12, 2022 updated by: Ru-Lan Hsieh, Taipei Medical University

Effects of Family Workshops on Children With Global Developmental Delays and Their Parents

To investigate the therapeutic effects of family workshops on children with global developmental delays and their parents by the analysis of the previously conducted workshops.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

To evaluate the effects of family workshops for children aged 18-36 months old with language developmental delays conducted from Jan 2014 Jan to Dec 2018, by the data analysis.

The participants were children with global developmental delay (language delay with at least one delay in motor, cognitive function, or emotional and social functioning) and their parents in the workshops.

The family workshops were conducted with 5 courses, with 6-7 families in one course, a 2-hour session per week, for 6 weeks.

Effects:

  1. Investigate the therapeutic effects of workshops for children with global developmental delays
  2. Investigate the therapeutic effects of workshops for the parents of children with global developmental delays

Study Type

Interventional

Enrollment (Anticipated)

101

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Hsieh, MD

Study Locations

      • Taipei, Taiwan, 111-01
        • Shin Kong Wu Ho-Su Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 3 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children aged 18-36 months old with global developmental delays (language developmental delay, with motor, cognition, or social and emotional developmental delays) Parents and children attended the one 2 hour-session of workshop per week for 6 weeks

Exclusion Criteria:

  • Less than 18 months old or older than 36 months old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Family workshops with 5 courses, with 6-7 families in one course, 2 hours per session, one time per week, for a total of 6 weeks.
Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pediatric Outcome Data Collection Instrument
Time Frame: scores change of Pediatric Outcome Data Collection Instrument from baseline to 6 weeks after treatment
measure the functional performance of children, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change of Pediatric Outcome Data Collection Instrument from baseline to 6 weeks after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mandarin-Chinese Communicative Developmental Inventory
Time Frame: percent change of Mandarin-Chinese Communicative Developmental Inventory from baseline to 6 weeks after treatment
assess communication function of children, <10% indicates delayed development, 10% or more than 10% indicates normal development
percent change of Mandarin-Chinese Communicative Developmental Inventory from baseline to 6 weeks after treatment
Peabody Developmental Motor Scale
Time Frame: scores change of Peabody Developmental Motor Scale from baseline to 6 weeks after treatment
assess fine motor function of children, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change of Peabody Developmental Motor Scale from baseline to 6 weeks after treatment
Emotional Competency Rating Scale
Time Frame: scores change of Emotional Competency Rating Scale from baseline to 6 weeks after treatment
assess the emotional function of children, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change of Emotional Competency Rating Scale from baseline to 6 weeks after treatment
Pediatric Evaluation of Disability Inventory
Time Frame: scores change of Pediatric Evaluation of Disability Inventory from baseline to 6 weeks after treatment
assess the functional skill attainment of children, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change of Pediatric Evaluation of Disability Inventory from baseline to 6 weeks after treatment
Pediatric Daily Occupation Scale
Time Frame: scores change Pediatric Daily Occupation Scale from baseline to 6 weeks after treatment
assess the occupational performance in the daily life of children, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change Pediatric Daily Occupation Scale from baseline to 6 weeks after treatment
Pediatric Quality of Life Inventory-Geriatric Core Scale
Time Frame: scores change ofPediatric Quality of Life Inventory-Geriatric Core Scale from baseline to 6 weeks after treatment
assess the quality of life of children, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change ofPediatric Quality of Life Inventory-Geriatric Core Scale from baseline to 6 weeks after treatment
Pediatric Quality of Life Inventory-Family Impact Module
Time Frame: scores change of Pediatric Quality of Life Inventory-Family Impact Module from baseline to 6 weeks after treatment
assess the impact of pediatric conditions on family functioning and parental quality of life, the minimum and maximum values range from 1 to 100, higher scores mean a better outcome
scores change of Pediatric Quality of Life Inventory-Family Impact Module from baseline to 6 weeks after treatment
Parental satisfaction questionnaire
Time Frame: scores of Parental satisfaction questionnaire after treatment
assess the parents' satisfaction with the workshops, with scores ranging from 1-to 100, higher scores mean a higher satisfaction
scores of Parental satisfaction questionnaire after treatment
Caregiver Strain Index
Time Frame: scores change of Caregiver Strain Index from baseline to 6 weeks after treatment
assess family strain, the minimum and maximum values range from 1 to 100, higher scores mean a worse outcome
scores change of Caregiver Strain Index from baseline to 6 weeks after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hsieh, MD, Shin Kong Wu Ho-Su Memorial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 10, 2022

Primary Completion (Anticipated)

August 1, 2022

Study Completion (Anticipated)

August 1, 2022

Study Registration Dates

First Submitted

June 8, 2022

First Submitted That Met QC Criteria

June 12, 2022

First Posted (Actual)

June 14, 2022

Study Record Updates

Last Update Posted (Actual)

June 14, 2022

Last Update Submitted That Met QC Criteria

June 12, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SKH-111-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Global Developmental Delay

Clinical Trials on Family workshop

3
Subscribe